文献速递银屑病与炎症性皮肤病

瑞莎珠单抗与阿普米司特治疗中度斑块状银屑病比较

Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
PubMed 文献 · Br J Dermatol · 2023-01-01

IMMpulse研究是一项52周、IV期、多中心、随机、开放标签、疗效评估者盲法试验,纳入适合系统治疗的中度斑块状银屑病成人患者。结果显示,第16周瑞莎珠单抗组PASI 90和sPGA 0/1应答率均显著优于阿普米司特组;阿普米司特第16周PASI 75无应答者换用瑞莎珠单抗后第52周PASI 90应答率亦显著更高。

要点

  • 第16周瑞莎珠单抗组PASI 90应答率55.9%,阿普米司特组5.1%。
  • 第16周瑞莎珠单抗组sPGA 0/1应答率75.4%,阿普米司特组18.4%。
  • 阿普米司特PASI 75无应答者换用瑞莎珠单抗后第52周PASI 90应答率72.3%。

核心结论

  • 对于中度银屑病患者,瑞莎珠单抗疗效优于阿普米司特,包括既往阿普米司特治疗未获益者。
  • 瑞莎珠单抗安全性特征与既往研究相似,未发现新的安全性信号。

研究设计与样本

  • 52周、IV期、多中心、随机、开放标签、疗效评估者盲法研究(NCT04908475)。
  • 纳入≥18岁、诊断中度慢性斑块状银屑病≥6个月且适合系统治疗的患者。
  • 患者按1:2随机接受皮下瑞莎珠单抗(150 mg,第0和4周)或口服阿普米司特(30 mg每日两次)。
  • 第16周时,所有阿普米司特治疗患者按1:1重新随机分配至瑞莎珠单抗或阿普米司特,按第16周PASI 75应答分层。

主要发现

  • 基线时,瑞莎珠单抗组118例,阿普米司特组234例。
  • 第16周,瑞莎珠单抗组PASI 90应答率55.9%(95%CI 47.0-64.9),阿普米司特组5.1%(95%CI 2.3-8.0)。
  • 第16周,瑞莎珠单抗组sPGA 0/1应答率75.4%(95%CI 67.7-83.2),阿普米司特组18.4%(95%CI 13.4-23.3)。
  • B期,阿普米司特第16周PASI 75无应答者中,83例换用瑞莎珠单抗,78例继续阿普米司特。
  • 第52周,换用瑞莎珠单抗者PASI 90应答率72.3%(95%CI 62.7-81.9),继续阿普米司特者2.6%(95%CI 0.0-6.1)。

关键数值与推荐

  • 共同主要结局(A期第16周):PASI 90应答率和sPGA 0/1(较基线改善≥2级)。
  • B期第52周主要终点:阿普米司特第16周PASI 75无应答者的PASI 90应答率。

临床怎么用

  • 对于适合系统治疗的中度斑块状银屑病成人患者,瑞莎珠单抗在PASI 90和sPGA 0/1应答上优于阿普米司特。
  • 阿普米司特治疗第16周未达PASI 75应答者,换用瑞莎珠单抗可提高第52周PASI 90应答率。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment of psoriasis with risankizumab has demonstrated superior efficacy to other treatments, such as adalimumab, ustekinumab and secukinumab. OBJECTIVES: This study compared the efficacy and safety of risankizumab and apremilast in adults with moderate plaque psoriasis eligible for systemic therapy. It also evaluated the efficacy and safety of switching to risankizumab vs. continuing apremilast in patients who did not achieve ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75 nonresponders) after 16 weeks of treatment with apremilast. METHODS: This 52-week, phase IV, multicentre, randomized, open-label, efficacy assessor-blinded study (NCT04908475) enrolled patients (aged ≥ 18 years) with a diagnosis of moderate chronic plaque psoriasis (≥ 6 months) and who were candidates for systemic therapy. The enrolled patients (randomized 1 : 2) received subcutaneous risankizumab (150 mg at weeks 0 and 4) or oral apremilast (30 mg twice daily). At week 16, all patients treated with apremilast were re-randomized (1 : 1) to risankizumab or apremilast, stratified by week-16 PASI 75 response. The co-primary outcomes in period A at week 16 were the achievement of ≥ 90% improvement in Psoriasis Area and Severity Index (PASI 90) and static Physician's Global Assessment (sPGA) 0/1 with a two-grade or better improvement from baseline. At week 52, the primary endpoint in period B was the achievement of PASI 90 in PASI 75 nonresponders with apremilast at week 16. Safety was monitored throughout the study. All patients who received one dose of treatment were included in the efficacy and safety analysis. RESULTS: At baseline, 118 and 234 patients were assigned to receive risankizumab and apremilast, respectively. At week 16, PASI 90 was achieved by 55.9% [95% confidence interval (CI) 47.0-64.9] and 5.1% (95% CI 2.3-8.0), and sPGA 0/1 by 75.4% (95% CI 67.7-83.2) and 18.4% (95% CI 13.4-23.3), respectively. In period B, among PASI 75 nonresponders with apremilast at week 16, 83 switched to risankizumab and 78 continued apremilast. At week 52, 72.3% (95% CI 62.7-81.9) who switched to risankizumab achieved PASI 90 vs. 2.6% (95% CI 0.0-6.1) who continued apremilast. The most frequent adverse events (reported in ≥ 5%) in risankizumab-treated patients were COVID-19 infection and nasopharyngitis. Diarrhoea, nausea and headache were most frequent among apremilast-treated patients. CONCLUSIONS: For patients with moderate psoriasis, treatment with risankizumab demonstrated superior efficacy to those treated with apremilast, including those who did not benefit from prior treatment with apremilast. The safety profile of risankizumab was similar to prior studies, and no new safety signals were identified. These results show that, compared with apremilast, risankizumab treatment can significantly improve clinical outcomes in systemic-eligible patients with moderate psoriasis.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Stein Gold LF, Bagel J, Tyring SK, et al. Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse). Br J Dermatol. 2023. PMID: 37488811. doi:10.1093/bjd/ljad252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。